Edgewise Therapeutics, Inc. Operating Cash Flow
Edgewise Therapeutics, Inc. (EWTX) reported Operating Cash Flow of -$85.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Edgewise Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$42.47M.
- Edgewise Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$42.54M.
- Edgewise Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$38.59M.
- Edgewise Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$34.78M.
- Edgewise Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$143.82M.
- Edgewise Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$109.03M.
- Edgewise Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$91.95M.
- Edgewise Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$52.63M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$42.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$85.01M 10-Q · filed 2026-08-06 | -$123.60M derived: sum of 3 quarters · filed 2026-08-06 | -$158.38M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$42.54M 10-Q · filed 2026-05-07 | -$81.14M derived: sum of 2 quarters · filed 2026-05-07 | -$115.91M derived: sum of 3 quarters · filed 2026-05-07 | -$148.49M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$38.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$73.37M derived: sum of 2 quarters · filed 2026-02-26 | -$105.95M derived: sum of 3 quarters · filed 2026-08-06 | -$143.82M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$34.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$67.36M derived: sum of 2 quarters · filed 2026-08-06 | -$105.22M 10-Q · filed 2025-11-06 | -$132.18M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$32.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$70.45M 10-Q · filed 2026-08-06 | -$97.41M derived: sum of 3 quarters · filed 2026-08-06 | -$124.78M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$37.87M 10-Q · filed 2026-05-07 | -$64.82M derived: sum of 2 quarters · filed 2026-05-07 | -$92.20M derived: sum of 3 quarters · filed 2026-05-07 | -$118.30M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$26.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$54.33M derived: sum of 2 quarters · filed 2026-02-26 | -$80.43M derived: sum of 3 quarters · filed 2026-02-26 | -$109.03M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$27.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$53.47M derived: sum of 2 quarters · filed 2025-11-06 | -$82.07M 10-Q · filed 2025-11-06 | -$108.90M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | -$26.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$54.70M 10-Q · filed 2025-08-07 | -$81.53M derived: sum of 3 quarters · filed 2026-02-26 | -$103.58M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$28.60M 10-Q · filed 2025-05-08 | -$55.43M derived: sum of 2 quarters · filed 2026-02-26 | -$77.49M derived: sum of 3 quarters · filed 2026-02-26 | -$97.72M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | -$26.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$48.89M derived: sum of 2 quarters · filed 2026-02-26 | -$69.12M derived: sum of 3 quarters · filed 2026-02-26 | -$91.95M 10-K · filed 2026-02-26 | |
| 2023-09-30 | -$22.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$42.29M derived: sum of 2 quarters · filed 2024-11-07 | -$65.12M 10-Q · filed 2024-11-07 | -$76.97M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$20.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$43.06M 10-Q · filed 2024-08-08 | -$54.91M derived: sum of 3 quarters · filed 2024-08-08 | -$66.88M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$22.83M 10-Q · filed 2024-05-09 | -$34.68M derived: sum of 2 quarters · filed 2024-05-09 | -$46.64M derived: sum of 3 quarters · filed 2024-05-09 | -$62.89M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$11.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$23.82M derived: sum of 2 quarters · filed 2024-02-22 | -$40.06M derived: sum of 3 quarters · filed 2024-02-22 | -$52.63M 10-K · filed 2024-02-22 | |
| 2022-09-30 | -$11.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$28.21M derived: sum of 2 quarters · filed 2023-11-09 | -$40.78M 10-Q · filed 2023-11-09 | -$40.81M 10-Q · filed 2022-11-03 | -$50.20M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$16.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$28.82M 10-Q · filed 2023-08-10 | -$38.24M derived: sum of 3 quarters · filed 2023-08-10 | -$46.50M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$12.57M 10-Q · filed 2023-05-11 | -$21.99M derived: sum of 2 quarters · filed 2023-05-11 | -$30.25M derived: sum of 3 quarters · filed 2023-05-11 | -$40.02M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$9.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$17.68M derived: sum of 2 quarters · filed 2023-02-23 | -$27.45M derived: sum of 3 quarters · filed 2023-02-23 | -$33.51M 10-K · filed 2023-02-23 | |
| 2021-09-30 | -$8.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$18.03M derived: sum of 2 quarters · filed 2022-11-03 | -$24.09M 10-Q · filed 2022-11-03 | -$28.73M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | -$9.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$15.83M 10-Q · filed 2022-08-04 | -$20.46M derived: sum of 3 quarters · filed 2022-08-04 | -$23.74M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$6.06M 10-Q · filed 2022-05-11 | -$10.70M derived: sum of 2 quarters · filed 2022-05-11 | -$13.97M derived: sum of 3 quarters · filed 2022-05-11 | -$17.95M derived: sum of 4 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$4.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$7.91M derived: sum of 2 quarters · filed 2022-02-24 | -$11.89M derived: sum of 3 quarters · filed 2022-02-24 | -$14.63M 10-K · filed 2022-02-24 | |
| 2020-09-30 | -$3.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$7.26M derived: sum of 2 quarters · filed 2021-11-10 | -$10.00M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$6.72M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | -$2.74M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |